Zanubrutinib is recommended, within its marketing authorisation, as an option for treating marginal zone lymphoma in adults who have had at least 1 anti‑CD20-based treatment. It is only recommended if the company provides it according to the commercial arrangement.
Why the committee made this recommendation
Standard care for marginal zone lymphoma in adults who have had at least 1 anti‑CD20-based treatment is rituximab with or without chemotherapy, or chemotherapy alone.
Zanubrutinib has not been directly compared in a clinical trial with standard care. An indirect comparison of zanubrutinib with standard care suggests that zanubrutinib increases how long people have before their lymphoma gets worse and how long they live.
The cost-effectiveness estimates for zanubrutinib compared with standard care are within the range NICE normally considers an acceptable use of NHS resources. So, zanubrutinib is recommended.